Omega Diagnostics Group PLC US expansion update

TIDMODX

RNS Number : 8680L

Omega Diagnostics Group PLC

06 January 2023

OMEGA DIAGNOSTICS GROUP PLC

("Omega", the "Company" or the "Group")

US expansion update

Maiden US Laboratory FoodPrint(R) installation,

Appointment of US importer for FoodPrint(R) and

First PO from US CLIA certified Lab heralds start of US expansion

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the maiden purchase order ('PO') for its FoodPrint(R) system from a CLIA certified ('Clinical Laboratory Improvement Amendments') laboratory in the United States, and has appointed a new US importer for FoodPrint(R) kits.

Using a small finger prick of blood, the FoodPrint(R) test can quickly identify an individual's unique food sensitivity reactions, allowing the patient to adjust and plan to a new diet and address IgG-mediated food sensitivities. FoodPrint(R) analyses up to 222 foods for IgG antibodies and is trusted by more than 150 laboratories worldwide, to help fast track a guided elimination diet allowing a more focused and actionable result for practitioners and their patients.

The Board expects installation at the laboratory to commence later this month and after a period of validation and gaining necessary approvals, the processing of tests to begin later this quarter. As well as being CLIA certified, the laboratory receiving the system is also College of American Pathologists accredited and specialises in providing functional tests for both consumers and healthcare practitioners.

Omega has also secured an importer for FoodPrint(R) kits into the USA. The importer will import kits for the CLIA laboratory as well as for Omega's own direct channels in future.

Although the value of this initial PO is circa GBP50,000, the US market is a key area of focus for Omega's growth strategy and this installation will be the first in the US market in over seven years, representing the beginning of Omega's planned expansion into the USA.

Jag Grewal, CEO of Omega Diagnostics, said: "The US is the single largest market for food sensitivity testing globally, with an ever-increasing demand for personalised medicine, and is a focus area for our growth plans. This installation reflects a key milestone in our expansion plans, the receiving laboratory is ideally placed to commercialise FoodPrint(R) in the US market as they are already providing a range of other functional tests. The appointment of the US importer will act as a foundation for our expansion into the region.

"Once the system has been commissioned, we plan to collaborate closely with our laboratory partner to ensure FoodPrint(R) is promoted effectively through their existing healthcare practitioner and direct to consumer channels."

Contacts:

 
 Omega Diagnostics Group PLC                                           www.omegadx.com 
 Jag Grewal, Chief Executive Officer                                   via Walbrook PR 
 Chris Lea, Chief Financial Officer 
 
 
 finnCap Ltd                                                        Tel: [phone] 
 Geoff Nash/Edward Whiley/George Dollemore (Corporate 
  Finance) 
 Alice Lane/Charlotte Sutcliffe 
  (ECM) 
 
 
 Walbrook PR Limited                        Tel: [phone] or [e-mail] 
 Paul McManus                                                       Mob: [phone] 
 Lianne Applegarth                                                  Mob: [phone] 
 Sam Allen                                                          Mob: [phone] 
 
 

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition .

www.omegadx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDBAMLTMTTMBAJ

(END) Dow Jones Newswires

January 06, 2023 02:00 ET (07:00 GMT)